ABSTRACT
Adenosine-to-inosine (A-to-I) editing is a prevalent post-transcriptional RNA modification within the brain. Yet, most research has relied on postmortem samples, assuming it is an accurate representation of RNA biology in the living brain. We challenge this assumption by comparing A-to-I editing between postmortem and living prefrontal cortical tissues. Major differences were found, with over 70,000 A-to-I sites showing higher editing levels in postmortem tissues. Increased A-to-I editing in postmortem tissues is linked to higher ADAR1 and ADARB1 expression, is more pronounced in non-neuronal cells, and indicative of postmortem activation of inflammation and hypoxia. Higher A-to-I editing in living tissues marks sites that are evolutionarily preserved, synaptic, developmentally timed, and disrupted in neurological conditions. Common genetic variants were also found to differentially affect A-to-I editing levels in living versus postmortem tissues. Collectively, these discoveries illuminate the nuanced functions and intricate regulatory mechanisms of RNA editing within the human brain.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the NIA: 1R01AG069976-01, Charney AW; 5R03AG080170-02; Breen, MS. The Michael J. Fox Foundation (Grant 18232), National Institute of Mental Health (R01MH109897)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All human subjects research was carried out under STUDY-13-00415 of the Human Research Protection Program at the Icahn School of Medicine at Mount Sinai and was approved by the Icahn School of Medicine at Mount Sinai Institutional Review Board. The study design and conduct complied with all relevant regulations. Research Participants in the living cohort provided informed consent for sample collection, genomic profiling, clinical data extraction from medical records and public sharing of de-identified data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The Living Brain Project RNA-sequencing data generated in this study have been deposited in the Synapse database under accession code syn26337520 [https://www.synapse.org/#!Synapse:syn26337520]. Secondary data analysis was carried out for several additional data resources, which are also publicly available with accession codes described above within each corresponding methods section. In brief, datasets subjected to secondary data analysis are available at Synapse under the accession numbers syn18934100, syn7416949, syn8365527, syn8298777, syn25716684, at GEO under the accession number GSE112137, and at dbGaP under the accession number phs000424.v8
